secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108909
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA Q2 R&D $4.9M, initiates Phase 3 IFx-2.0 trial, acquires Kineta VISTA mAb
-------------------------------------------------------------------------------

- Completed acquisition of Kineta; VISTA mAb (TBS-2025) Phase 2 AML trial planned for 2H 2025.
- Initiated Phase 3 accelerated approval trial of IFx-2.0 with Keytruda in MCC under FDA SPA.
- Raised $12.5M equity financing plus $3.0M from warrant exercise in June 2025; shares outstanding ~49.9M.
- R&D expenses $4.9M (Q2 2025) vs $2.8M (Q2 2024); operating cash outflow ($10.9M) for 6 months.
- Added to Russell 3000/2000 indices in June 2025; targets Phase 3 topline results 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/0000950170-25-108909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/hura-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer